Literature DB >> 9125533

Anticarrier immunity suppresses the antibody response to polysaccharide antigens after intranasal immunization with the polysaccharide-protein conjugate.

C Bergquist1, T Lagergård, J Holmgren.   

Abstract

We have conjugated cholera toxin (CT) B subunit (CTB) to dextran and studied the effect in mice of previous immunization with CT and CTB on the response to dextran after intranasal immunizations with conjugate. Preexisting immunity to CTB was found to inhibit both the lung mucosal response and serum antibody response to dextran, but this effect could be overcome by using a higher dose of conjugate and delaying the conjugate immunization until the CTB antibody titers had declined. The role of anti-CTB antibodies on the mucosal surface was probably to prevent uptake of the conjugate through a mechanism of immune exclusion. Passively transferred serum antibodies against CTB, on the other hand, suppressed both the serum response and the local antibody response against CTB but did not affect the response to dextran after intranasal immunization with conjugate.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9125533      PMCID: PMC175177          DOI: 10.1128/iai.65.5.1579-1583.1997

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  29 in total

1.  Maternal antibodies partly inhibit an active antibody response to routine tetanus toxoid immunization in infants.

Authors:  H Sarvas; S Kurikka; I J Seppälä; P H Mäkelä; O Mäkelä
Journal:  J Infect Dis       Date:  1992-05       Impact factor: 5.226

2.  Oral administration of a streptococcal antigen coupled to cholera toxin B subunit evokes strong antibody responses in salivary glands and extramucosal tissues.

Authors:  C Czerkinsky; M W Russell; N Lycke; M Lindblad; J Holmgren
Journal:  Infect Immun       Date:  1989-04       Impact factor: 3.441

Review 3.  Actions of cholera toxin and the prevention and treatment of cholera.

Authors:  J Holmgren
Journal:  Nature       Date:  1981-07-30       Impact factor: 49.962

4.  Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens.

Authors:  N Lycke; J Holmgren
Journal:  Immunology       Date:  1986-10       Impact factor: 7.397

5.  Oral administration of cholera toxin-Sendai virus conjugate potentiates gut and respiratory immunity against Sendai virus.

Authors:  X P Liang; M E Lamm; J G Nedrud
Journal:  J Immunol       Date:  1988-09-01       Impact factor: 5.422

6.  Human serum activities against Hemophilus influenzae, type b.

Authors:  P Anderson; R B Johnston; D H Smith
Journal:  J Clin Invest       Date:  1972-01       Impact factor: 14.808

7.  Immune response of the female rat genital tract after oral and local immunization with keyhole limpet hemocyanin conjugated to the cholera toxin B subunit.

Authors:  A C Menge; S M Michalek; M W Russell; J Mestecky
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

Review 8.  Immunocompetent cells of the upper airway: functions in normal and diseased mucosa.

Authors:  P Brandtzaeg
Journal:  Eur Arch Otorhinolaryngol       Date:  1995       Impact factor: 2.503

9.  Anti-capsular polysaccharide antibodies reduce nasopharyngeal colonization by Haemophilus influenzae type b in infant rats.

Authors:  M Kauppi; L Saarinen; H Käyhty
Journal:  J Infect Dis       Date:  1993-02       Impact factor: 5.226

10.  Induction of compartmentalized B-cell responses in human tonsils.

Authors:  M Quiding-Järbrink; G Granström; I Nordström; J Holmgren; C Czerkinsky
Journal:  Infect Immun       Date:  1995-03       Impact factor: 3.441

View more
  10 in total

1.  Combined conjugate vaccines: enhanced immunogenicity with the N19 polyepitope as a carrier protein.

Authors:  Karin Baraldo; Elena Mori; Antonella Bartoloni; Francesco Norelli; Guido Grandi; Rino Rappuoli; Oretta Finco; Giuseppe Del Giudice
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

2.  Mucosal adjuvant properties of the Shigella invasin complex.

Authors:  Robert W Kaminski; K Ross Turbyfill; Edwin V Oaks
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

3.  Unique cellular and humoral immunogenicity profiles generated by aerosol, intranasal, or parenteral vaccination in rhesus macaques.

Authors:  Diane L Bolton; Kaimei Song; Georgia D Tomaras; Srinivas Rao; Mario Roederer
Journal:  Vaccine       Date:  2016-12-29       Impact factor: 3.641

4.  Intranasal administration of a meningococcal outer membrane vesicle vaccine induces persistent local mucosal antibodies and serum antibodies with strong bactericidal activity in humans.

Authors:  B Haneberg; R Dalseg; E Wedege; E A Høiby; I L Haugen; F Oftung; S R Andersen; L M Naess; A Aase; T E Michaelsen; J Holst
Journal:  Infect Immun       Date:  1998-04       Impact factor: 3.441

5.  Group B Streptococcus capsular polysaccharide-cholera toxin B subunit conjugate vaccines prepared by different methods for intranasal immunization.

Authors:  X Shen; T Lagergård; Y Yang; M Lindblad; M Fredriksson; J Holmgren
Journal:  Infect Immun       Date:  2001-01       Impact factor: 3.441

6.  Protective immunity of microsphere-based mucosal vaccines against lethal intranasal challenge with Streptococcus pneumoniae.

Authors:  S Y Seong; N H Cho; I C Kwon; S Y Jeong
Journal:  Infect Immun       Date:  1999-07       Impact factor: 3.441

Review 7.  Bacillus subtilis: a temperature resistant and needle free delivery system of immunogens.

Authors:  Hellen Amuguni; Saul Tzipori
Journal:  Hum Vaccin Immunother       Date:  2012-06-15       Impact factor: 3.452

8.  Serotype-specific and age-dependent generation of pneumococcal polysaccharide-specific memory B-cell and antibody responses to immunization with a pneumococcal conjugate vaccine.

Authors:  Elizabeth A Clutterbuck; Sarah Oh; Mainga Hamaluba; Sharon Westcar; Peter C L Beverley; Andrew J Pollard
Journal:  Clin Vaccine Immunol       Date:  2007-11-21

9.  Intranasal immunization of mice with group B streptococcal protein rib and cholera toxin B subunit confers protection against lethal infection.

Authors:  Charlotte Larsson; Jan Holmgren; Gunnar Lindahl; Charlotta Bergquist
Journal:  Infect Immun       Date:  2004-02       Impact factor: 3.441

10.  Development of Safe and Non-Self-Immunogenic Mucosal Adjuvant by Recombinant Fusion of Cholera Toxin A1 Subunit with Protein Transduction Domain.

Authors:  Byoung-Shik Shim; In Su Cheon; Eugene Lee; Sung-Moo Park; Youngjoo Choi; Dae-Im Jung; Eunji Yang; Jung-Ah Choi; June Young Chun; Jae-Ouk Kim; Cheol-Heui Yun; Cecil Czerkinsky; Man Ki Song
Journal:  J Immunol Res       Date:  2018-03-07       Impact factor: 4.818

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.